DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts give DiaMedica Therapeutics a “Moderate Buy” consensus: Four of five analysts rate the stock a buy, while one rates it a sell. The average 12-month price target is $12.00, compared with the reported share price of $6.74.
• Institutional ownership increased: Several investors raised their stakes or initiated positions, including Millennium Management, Geode Capital Management, State Street and Royal Bank of Canada. Institutional investors collectively own 10.12% of the company.
• DiaMedica reported quarterly EPS of -$0.19, beating the consensus estimate of -$0.20. The clinical-stage biotech is developing DM199, an investigational therapy for conditions including acute ischemic stroke.

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $12.00.

A number of brokerages have commented on DMAC. HC Wainwright reaffirmed a "buy" rating and issued a $12.00 price objective on shares of DiaMedica Therapeutics in a report on Tuesday, August 11th. Weiss Ratings reissued a "sell (d-)" rating on shares of DiaMedica Therapeutics in a research report on Friday, July 17th. Finally, Wall Street Zen upgraded shares of DiaMedica Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Saturday, June 6th.

Institutional Trading of DiaMedica Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Millennium Management LLC bought a new position in shares of DiaMedica Therapeutics during the third quarter worth approximately $8,157,000. Geode Capital Management LLC raised its position in shares of DiaMedica Therapeutics by 7.4% in the fourth quarter. Geode Capital Management LLC now owns 764,255 shares of the company's stock valued at $6,085,000 after buying an additional 52,437 shares in the last quarter. State Street Corp boosted its stake in shares of DiaMedica Therapeutics by 31.7% in the fourth quarter. State Street Corp now owns 627,771 shares of the company's stock valued at $4,997,000 after buying an additional 151,188 shares during the period. Royal Bank of Canada boosted its stake in shares of DiaMedica Therapeutics by 46,879.1% in the first quarter. Royal Bank of Canada now owns 155,031 shares of the company's stock valued at $588,000 after buying an additional 154,701 shares during the period. Finally, Osaic Holdings Inc. grew its position in DiaMedica Therapeutics by 374.7% during the second quarter. Osaic Holdings Inc. now owns 144,290 shares of the company's stock worth $563,000 after buying an additional 113,893 shares in the last quarter. Institutional investors own 10.12% of the company's stock.

DiaMedica Therapeutics Stock Up 3.4%

Shares of DMAC stock opened at $6.74 on Wednesday. DiaMedica Therapeutics has a 12-month low of $5.14 and a 12-month high of $10.42. The company has a market capitalization of $363.49 million, a PE ratio of -9.36 and a beta of 1.01. The firm has a 50 day moving average price of $6.85 and a two-hundred day moving average price of $6.82.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.01. As a group, research analysts expect that DiaMedica Therapeutics will post -0.84 EPS for the current year.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc NASDAQ: DMAC is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company's lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica's research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source